Novartis AG and Les Laboratoires Servier SAS have identified proteolysis targeting chimeras (PROTACs) compounds comprising E3 ubiquitin ligase-binding moiety covalently bonded to Bcl-2-like protein 1 (BCL2L1)-targeting moiety through a linker reported to be useful for the treatment of cancer.